CVKD
Cadrenal Therapeutics, Inc. Common Stock
There isn't enough reported data to score CVKD yet.
CVKD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CVKD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CVKD PE Valuation
CVKD has no meaningful PE right now: it lost money over the past year.
CVKD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect CVKD's losses to shrink, with revenue holding steady.
CVKD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.86 | +$4.08 |
| Q1 2026 | -$5.59 | +$3.73 |
| Q4 2025 | -$6.64 | +$2.09 |
| Q3 2025 | -$8.07 | -$1.03 |
| Q2 2025 | -$8.94 | -$3.03 |
| Q1 2025 | -$9.32 | -$4.31 |
| Q4 2024 | -$8.73 | +$1.98 |
| Q3 2024 | -$7.04 | +$9.02 |
CVKD is still losing money, but far less than before: $4.86 per share over the past year, against $16.06 at its worst in late 2023.
CVKD Quarterly Revenue
CVKD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2025 | -$4.7M | -$2.8M |
| Q1 2024 | -$1.8M | -$423.6K |
| Q4 2023 | -$694.4K | -$294.5K |
| Q3 2023 | -$627.8K | -$207.8K |
| Q1 2023 | -$1.4M | -$1.4M |
CVKD has burned cash in almost every quarter: −$13M over the past year, against −$5M the year before.
CVKD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +506K shares |
| 1 year | +58% | +1.1M shares |
| 3 years | +276% | +2.1M shares |
CVKD has 3M diluted shares, up 58% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q1 2022 | — |
CVKD Net Leverage
CVKD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CVKD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.9 | Neutral |
| Stochastic | 23.2 | Neutral |
CVKD's weekly RSI is 37 (neutral) and its Stochastic is 23 (neutral).
CVKD PE vs Healthcare Sector
CVKD has no meaningful PE right now: it lost money over the past year.
CVKD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.07 | 41% above |
| 20 week MA | $1.58 | 4.4% below |
| 50 week MA | $4.42 | 66% below |
| 100 week MA | $9.58 | 84% below |
| 200 week MA | $12.0 | 87% below |
CVKD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 87% below its 200-week average.
CVKD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $61.8 | $11.1 | -82% |
| 2024 | $11.1 | $16.2 | +45% |
| 2025 | $16.2 | $7.41 | -54% |
| 2026 YTD | $7.41 | $1.51 | -80% |
CVKD has finished lower in two of the last three years. It's down 80% so far in 2026.